Lidocain/Prilocain Adgc (Lidocaine, Prilocaine)

Lidocaine, together with prilocaine, blocks voltage‑gated sodium channels in neuronal membranes. By stabilising the inactive state of these channels, the drugs prevent sodium influx, which stops the generation and conduction of nerve impulses, resulting in temporary loss of sensation at the site of application.

The appropriate dose and the area of application are determined by the prescribing healthcare professional based on the specific procedure, patient age, and clinical context. The product should be applied only as directed on the label or by the prescriber.

Safety data for this topical combination in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician after evaluating the individual situation.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lidocain/Prilocain Adgc combines two amide‑type anesthetics, offering a broader spectrum of nerve blockade and often a faster onset compared with single‑agent products such as lidocaine alone. The combination can provide deeper anesthesia for certain procedures while maintaining a safety profile comparable to other topical agents when used as directed.

Store the product at room temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight and extreme temperatures. Keep the container tightly closed when not in use to maintain product stability.

The product is applied topically to the intended skin or mucous membrane area. The prescribed amount is spread evenly over the surface, usually with a sterile applicator, and left in place for the duration specified by the healthcare professional before the procedure begins.

Serious risks include systemic toxicity leading to central nervous system symptoms (e.g., seizures, dizziness) or cardiovascular depression, as well as rare but severe allergic reactions such as anaphylaxis and methemoglobinemia. Patients should be monitored for signs of systemic absorption, especially when large surface areas are treated.

Individuals with a known hypersensitivity to lidocaine, prilocaine, or any amide‑type local anesthetic should avoid this product. It is also contraindicated on broken or inflamed skin, in patients with certain metabolic disorders that predispose to methemoglobinemia, and in situations where excessive systemic absorption could occur without medical supervision.